Good news! Biotech company Moderna Inc. and government scientists at the National Institutes of Health report promising early results for coronavirus vaccine testing, currently in Phase 2 trials. A study published in the New England Journal of Medicine announced successful immune responses in all people who received the vaccine in March.

For our comprehensive coverage and latest updates on COVID-19 click here.

During Phase 1 human testing, researchers administered the vaccine to 45 healthy adults, ages 18-55. Volunteers were separated into three groups that each received two shots, of varying doses, 28 days apart. After the second dose, all participants developed “neutralizing antibodies.” Participant antibody levels were reportedly similar to antibody levels of recovered COVID-19 patients. Tests also presented an encouraging T-cell response in the immune system.

Phase 1 volunteers will continue to be evaluated for one year to see how long their COVID-19 immune responses last.